- September 03, 2018
08:00 PM EDT
- Organized By:
The Food and Drug Administration (FDA or the Agency) is announcing a public hearing on FDA's approach to enhancing competition and innovation in the biological products marketplace, including by facilitating greater availability of biosimilar and interchangeable products.
September 4, 2018
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
The Great Room B/C
Silver Spring, MD 20993-0002
The entrance for public meeting participants (non-FDA employees or contractors) is through Building 1, where routine security check procedures will be performed. For parking, security and other visitor information, please refer to Public Meetings at the FDA White Oak Campus.
Please use Eventbrite to register for in-person or webcast attendance .
If you need special accommodations due to a disability, please contact Allison Hoffman, Ph.D., at 301-796-9203 or OMPTFeedback@fda.hhs.gov no later than Friday, August 17, 2018.
Regardless of attendance at the public meeting, you can submit electronic or written comments to the public docket by Friday September 21, 2018. Submit electronic comments to Regulations.gov. Submit written comments to the Division of Docket’s Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.
If you have questions about registering for the meeting, contact Allison Hoffman, Ph.D., U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, phone: 301-796-9203, or email: OMPTFeedback@fda.hhs.gov.